Ubiquigent appoints Dr Xavier Jacq to Scientific Advisory Board

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced the appointment of Dr Xavier Jacq to its Scientific Advisory Board (SAB).

Related Keywords

Colombia ,United States ,France ,Philip Cohen ,John Davis ,Helen Walden ,Xavier Jacq ,Mission Therapeutics ,Cancer Biology At Colombia University ,Louis Pasteur University In Strasbourg ,Ubiquigent Limited ,Vp Scientific Affairs ,Scientific Advisory Board ,Professor Sir Philip ,Almac Discovery ,Dunad Therapeutics ,Senior Vice ,Chief Scientific Officer ,Louis Pasteur University ,Cancer Biology ,Colombia University ,Drug Discovery ,Herapeutics ,